文献速递泌尿生殖技术与安全PETCT

18F-PSMA PET/CT用于mCRPC治疗决策的健康经济学前期分析

Laying the groundwork for future health economic evaluation of [18F]PSMA PET/CT in guiding treatment decisions for metastatic castration-resistant prostate cancer patients.
PubMed 文献 · Eur J Radiol · 2026-09-03

本研究对60例转移性去势抵抗性前列腺癌患者进行事后分析,评估18F-PSMA-1007 PET/CT对治疗决策和医院成本的影响。53例停止治疗,其中28例因疾病进展、7例因毒性、18例完成化疗周期。PSMA PET/CT费用为1286欧元,研究者认为需通过正式成本效果分析明确其能否避免无效治疗或节约治疗相关费用。

要点

  • PSMA PET/CT单次费用为1286欧元,明显高于常规治疗月均费用中的阿比特龙1826欧元但低于恩扎卢胺3652欧元。
  • 治疗中断最常见原因为疾病进展28例,阅片报告应重点评估进展征象以支持决策。
  • PSMA PET/CT在治疗路径快速变化的背景下解读成本时需要结合具体情境,不能孤立判断。

核心结论

  • PSMA PET/CT有助于指导mCRPC治疗决策,但其费用相对于常规治疗成本较高,可否转化为避免无效治疗或治疗相关费用节省需通过正式成本效果分析验证。

研究设计与样本

  • 本研究为事后分析,纳入60例转移性去势抵抗性前列腺癌患者,采用医院视角估算每位患者的成本。

诊断标准与关键数值

  • 药物月费用分别为:阿比特龙1826欧元,恩扎卢胺3652欧元,化疗3190欧元。
  • PSMA PET/CT单次费用估计为1286欧元。
  • 60例患者中53例停止治疗,其中28例因疾病进展,7例因毒性,18例完成化疗周期。

临床应用与阅片要点

  • 在报告中识别疾病进展征象对mCRPC治疗中断决策至关重要,28例因进展停药提示影像在疗效评估中的核心作用。
  • PSMA PET/CT的费用需要与常规治疗成本以及新型靶向治疗费用联合判断。

局限性

  • 研究为单臂探索性事后分析,缺乏正式的成本效果分析设计。
  • 研究未直接比较使用与不使用PSMA PET/CT的患者在费用和治疗结局上的差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

INTRODUCTION: Recent study results of our group demonstrated that [18F]PSMA-1007 (PSMA) PET/CT outperforms PSA response in predicting overall survival in metastatic castration-resistant prostate cancer (mCRPC) patients. However, its health economic implications for guiding treatment decisions remained unclear. This post-hoc analysis explores the potential impact of PSMA PET/CT on treatment decisions and patient-level costs, highlighting its relevance for future health economic evaluations.

METHODS: Time from therapy initiation to therapy discontinuation and the reasons for discontinuation were studied. A swimmer plot visualised individual patient timelines and censored events. Hospital-perspective cost estimates were determined per patient.

RESULTS: Among 60 patients, 53 discontinued therapy: 28 due to disease progression, 7 due to toxicity, and 18 after completing chemotherapy cycles. Seven patients remained on-treatment at the time of analysis. Costs varied by treatment duration and medication: monthly hospital costs were €1,826 for abiraterone, €3,652 for enzalutamide and €3,190 for chemotherapy. The cost of PSMA PET/CT was estimated at €1,286 and requires contextual evaluation within rapidly changing treatment pathways.

DISCUSSION: PSMA PET/CT helps inform treatment decisions, but its cost is considerable relative to the cost of conventional therapy. Whether the use of PSMA PET/CT translates into avoidance of ineffective therapy or in therapy-related cost savings should be studied in formal cost-effectiveness analysis. Cost savings are less evident where conventional treatment costs are low compared with novel (but costly) targeted therapy options. Standardised imaging protocols, multicentre data and population registries are essential to strengthen the evidence base and enable future health economic evaluation.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. van Mossel, van der Velden, Kleiburg, et al. Laying the groundwork for future health economic evaluation of [18F]PSMA PET/CT in guiding treatment decisions for metastatic castration-resistant prostate cancer patients. Eur J Radiol. 2026. PMID: 42731497. doi:10.1016/j.ejrad.2026.113213

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。